TUBA1C

Tubulin alpha-1C chain · Q9BQE3 · TUBA1C on Sugi Atlas →

132,215 patent compounds predicted against TUBA1C, 83,505 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Curacin A Curacin A (SCHEMBL61304) 1.00 20/20
Vintriptol Vintriptol (SCHEMBL93959) 1.00 15/20
Vindesine Vindesine (SCHEMBL4420) 0.85 13/20
Vindesine Vindesine (SCHEMBL4421) 0.85 13/20
Vindesine Vindesine (SCHEMBL4285) 0.85 12/20
SCHEMBL147173 SCHEMBL147173 0.50 12/20
SCHEMBL147174 SCHEMBL147174 0.50 12/20
Combretastatin Combretastatin (SCHEMBL19955) 1.00 9/20
Combretastatin Combretastatin (SCHEMBL19956) 1.00 9/20
SCHEMBL118593 SCHEMBL118593 0.69 9/20
Centaureidin Centaureidin (SCHEMBL9953) 1.00 8/20
Thiocolchicine Thiocolchicine (SCHEMBL43160) 1.00 8/20
Thiocolchicine Thiocolchicine (SCHEMBL43161) 1.00 8/20
SCHEMBL68067 SCHEMBL68067 0.62 8/20
Fosbretabulin Fosbretabulin (SCHEMBL66079) 0.61 8/20
Vinorelbine Vinorelbine (SCHEMBL4765) 1.00 7/20
Combretastatin A4 Combretastatin A4 (SCHEMBL18945) 1.00 7/20
Combretastatin A4 Combretastatin A4 (SCHEMBL18946) 1.00 7/20
Levofloxacin Anhydrous Levofloxacin Anhydrous (SCHEMBL15397) 0.98 7/20
Ofloxacin Ofloxacin (SCHEMBL24373) 0.98 7/20

Clinical trials — most relevant to TUBA1C by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer PHASE3COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) PHASE2/PHASE3ACTIVE_NOT_RECRUITING
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients. PHASE3COMPLETED
A Multicenter Study of NAP (AL-108) in Schizophrenia PHASE2COMPLETED
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer PHASE2COMPLETED
Biologic Correlative Taxotere/AC PHASE2COMPLETED
First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients PHASE2ACTIVE_NOT_RECRUITING
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer PHASE2UNKNOWN
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations PHASE2COMPLETED
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer PHASE1/PHASE2NOT_YET_RECRUITING
Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy PHASE2COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Study of ABT-751 in Patients With Refractory Hematologic Malignancies PHASE1COMPLETED
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer PHASE1COMPLETED
Exploratory Evaluation of [11C]MPC6827 EARLY_PHASE1COMPLETED
Effect of Low Dose of Colchicine on Platelet Reactivity nanCOMPLETED
Generating Intervals of Reference FFor Early Life Brain Biomarkers. nanRECRUITING
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting nanUNKNOWN
Diagnostic of Chemotherapy Induced Neuropathy in Children nanCOMPLETED
Correlation Between Autophagy-related Proteins and Inflammatory Markers in Hemodialysis Patients nanCOMPLETED
Effect of Non-chirurgical Periodontal Treatment on the Immune System From a Gender Perspective nanCOMPLETED
Genetic Study of Patients With Primary Ciliary Dyskinesia nanCOMPLETED
Diagnosis of Primary Ciliary Dyskinesia nanCOMPLETED
Evaluation of a Novel PET Radioligand to Image OGA nanCOMPLETED
The Relation of Microtubule-Associated Protein 2 and Cell Migration nanUNKNOWN
Mapping Disease Pathways for Biliary Atresia nanRECRUITING
Biomarkers and Validation of Selected Outcome Measures (CMTBiomarker) nanCOMPLETED
Myotubular Myopathy Genetic Testing Study nanCOMPLETED
Importance of the Microtubule Cytoskeleton in Oocyte Competence nanCOMPLETED
Perfusion-Induced Hyperthermia for Metastatic Carcinoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TUBA1C binder may also engage these)

ProteinNameSimilarity
Q6AYZ1 1.000 Q6AYZ1 →
P68373 1.000 P68373 →
P68360 1.000 P68360 →
Q94572 1.000 Q94572 →
P68370 1.000 P68370 →
P68361 1.000 P68361 →
Q28IX8 1.000 Q28IX8 →
Q2HJ86 1.000 Q2HJ86 →
Q5R1W4 1.000 Q5R1W4 →
P34690 1.000 P34690 →
TUBA3E Tubulin alpha-3E chain (EC 3.6.5.-) (Alpha-tu 1.000 landscape →
P05214 1.000 P05214 →
TUBA3C Tubulin alpha-3C chain (EC 3.6.5.-) (Alpha-tu 1.000 landscape →
Q68FR8 1.000 Q68FR8 →
Q8T6A5 1.000 Q8T6A5 →
Q5XIF6 1.000 Q5XIF6 →
Q25008 1.000 Q25008 →
P30436 1.000 P30436 →
P81948 1.000 P81948 →
P50719 1.000 P50719 →
Q9JJZ2 1.000 Q9JJZ2 →
Q8WQ47 1.000 Q8WQ47 →
P91910 1.000 P91910 →
P08070 1.000 P08070 →
P68369 1.000 P68369 →
P02552 1.000 P02552 →
P50258 1.000 P50258 →
P33625 1.000 P33625 →
Q56WH1 1.000 Q56WH1 →
P12543 1.000 P12543 →